Your browser doesn't support javascript.
loading
Fibroblastic rheumatism: an uncommon arthritis. A case-based review.
Pieta, A; Zioga, A; Skalkou, A; Venetsanopoulou, A I; Drosos, A A; Voulgari, P V.
Afiliación
  • Pieta A; Rheumatology Clinic, Department of Internal Medicine, University Hospital of Ioannina, School of Health Sciences, University of Ioannina, 45110, Ioannina, Greece.
  • Zioga A; Department of Pathology, University Hospital of Ioannina, Ioannina, Greece.
  • Skalkou A; Rheumatology Clinic, Department of Internal Medicine, University Hospital of Ioannina, School of Health Sciences, University of Ioannina, 45110, Ioannina, Greece.
  • Venetsanopoulou AI; Rheumatology Clinic, Department of Internal Medicine, University Hospital of Ioannina, School of Health Sciences, University of Ioannina, 45110, Ioannina, Greece.
  • Drosos AA; Rheumatology Clinic, Department of Internal Medicine, University Hospital of Ioannina, School of Health Sciences, University of Ioannina, 45110, Ioannina, Greece.
  • Voulgari PV; Rheumatology Clinic, Department of Internal Medicine, University Hospital of Ioannina, School of Health Sciences, University of Ioannina, 45110, Ioannina, Greece. pvoulgar@uoi.gr.
Rheumatol Int ; 42(6): 1097-1103, 2022 06.
Article en En | MEDLINE | ID: mdl-34611730
Fibroblastic rheumatism (FR) is an uncommon disease of the skin, characterized by the presence of non-tender cutaneous nodules accompanied often by other rheumatic manifestations. This condition shows male predominance, no age preference and unpredictable course, resulting frequently in permanent joint damage. A 60-year-old man came to our department with a 4-year history of multiple non-tender nodules and morning stiffness affecting mainly the upper extremities. Clinical examination revealed arthritis of the hands, confirmed by imaging tests. Laboratory exams were unremarkable. A skin nodule biopsy showed a dermal collagenous lesion with myxoid areas composed of spindle and stellate cells. Immunohistochemical staining demonstrated positivity for CD68 and negativity for CD34, S100, EMA and desmine. FR was diagnosed and the patient started methylprednisolone 16 mg/day. Hydroxychloroquine 400 mg/day and methotrexate 15 mg/weekly were further added as steroid-sparing agents with clinical benefit. Clinicians should be aware of this underreported entity, which can rapidly lead to irreversible deformities.
Asunto(s)
Palabras clave

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Artritis / Enfermedades Reumáticas Tipo de estudio: Diagnostic_studies Límite: Female / Humans / Male / Middle aged Idioma: En Revista: Rheumatol Int Año: 2022 Tipo del documento: Article País de afiliación: Grecia Pais de publicación: Alemania

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Artritis / Enfermedades Reumáticas Tipo de estudio: Diagnostic_studies Límite: Female / Humans / Male / Middle aged Idioma: En Revista: Rheumatol Int Año: 2022 Tipo del documento: Article País de afiliación: Grecia Pais de publicación: Alemania